monoclonal antibody hmn-14
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2000 (NCT00041639)
Timeline
Indications
Mechanism of action
CEACAM5 other
IgG1 MAb that induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Binds with high affinity to the restricted A3B3 domain (Gold group 3) found on CEACAM5.
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108501 ↗
Also known as
- (131i)-mn-14
- (131i)-mn-14
- cea-cide
- hmn-14
- hmn-14
- hmn-14
- immu 130
- immu 130
- immu-130
- immu-130
- labetuzumab
- labetuzumab
- labetuzumab
- labetuzumab
- labetuzumab
- mab hmn14
- mab hmn14
- monoclonal antibody hmn-14
- monoclonal antibody hmn-14
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01915472 | Phase 2 | Sep 1, 2013 | Immunomedics |
| NCT01605318 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | Immunomedics |
| NCT01270698 | Phase 1 | May 1, 2011 | Immunomedics |
| NCT00041691 | Phase 1 | Jul 12, 2002 | Immunomedics |
| NCT00041652 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2000 | Immunomedics |
| NCT00040599 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2000 | Immunomedics |
| NCT00041639 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2000 | Immunomedics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunomedics | For profit | 7 | 7 | 2 | 2000 |
1 organizations
Page 1 / 1